ArticleBioconjugate chemistry2016
Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment.
Article in Bioconjugate chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- Advanced hitchhiking nanomaterials for biomedical applications.Theranostics · 2023Review
- A Comparison of Evans Blue and 4-(Pharmaceutics · 2022Article
- Therapeutic Efficacy ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future.Frontiers in cell and developmental biology · 2022Review
- Strategies to expand peptide functionality through hybridisation with a small molecule component.RSC chemical biology · 2021Review
- GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.International journal of biological sciences · 2021Review
- Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics.MedChemComm · 2019Review
- Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin.Small (Weinheim an der Bergstrasse, Germany) · 2019Article
- Harnessing albumin as a carrier for cancer therapies.Advanced drug delivery reviews · 2018Review
- Revisiting amino acids and peptides as anti-glycation agents.MedChemComm · 2018Review
- Improving long-term subcutaneous drug delivery by regulating material-bioenvironment interaction.Advanced drug delivery reviews · 2018Review
- "Albumin Hitchhiking" with an Evans Blue Analog for Cancer Theranostics.Theranostics · 2018Article
- Evans Blue Dye: A Revisit of Its Applications in Biomedicine.Contrast media & molecular imaging · 2018Review
- A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.Theranostics · 2018Article
- Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy.Nature communications · 2017Article
- Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In the treatment of type 2 diabetes mellitus, it is very important to develop therapeutics with prolonged circulation half-life. Exendin-4 is a glucagon like peptide-1 receptor (GLP-1R) agonist that has been modified in different ways for imaging insulinoma and for treating type-2 diabetes. In this work, we synthesized a maleimide derivative of truncated Evans blue dye (MEB-C3-Mal) to conjugate with (Cys(40))exendin-4 to obtain a highly stable MEB-C3-(Cys(40))exendin-4 (denoted as Abextide II). Through in situ binding with endogenous albumin, Abextide II lowers blood glucose level and prolongs the hypoglycemic effect in a type 2 diabetes mouse model more than the FDA approved Albiglutide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.